

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: April 13, 2006 (use as many sheets as necessary)			Complete If Known		
			Application Number	09/782,721	
			Filing Date	2/12/2001	
			First Named Inventor	H. Michael Shepard	
			Group Art Unit	1623	
			Examiner Name	Crane, Lawrence E.	
			Attorney Docket Number	NB 2004.02 (060925-0402)	
Sheet	2	of	9		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
Pre	13	EP	0 095 294	A1	Beecham Group PLC	11-30-1983		
	14	EP	0 283 065	A1	Stichting REGA VZW	09-21-1988		
	15	RO	88451		Antibiotics Enperprise, Inc.	01-30-1986		✓
	16	WO	89/05817		Nucleic Acid Research Institute	06-29-1989		
	17	WO	92/20344		Glaxo Group Ltd.	11-26-1992		
	18	WO	95/01806		Kondratyev, A.	01-19-1995		
	19	WO	95/09865		Terrapin Technologies, Inc.	04-13-1995		
	20	WO	95/12678		Campaign Technology Limited	05-11-1995		
	21	WO	96/33168		Kumiai Chemical Industry Co. Ltd. et al.	10-24-1996		
	22	WO	99/06072		Boehringer Mannheim Corporation	02-11-1999		
Pre	23	WO	99/08110		NewBiotics, Inc.	02-18-1999		
	24	WO	99/37753		NewBiotics, Inc.	07-29-1999		
	25	WO	00/33888		Coulter Pharmaceutical, Inc.	06-15-2000		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
Pre	26	ASCHELE et al. "Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy" <i>J. Clin. Oncol.</i> (June 1999) 17(6):1760-1770	
	27	BAGSHAW, K.D. "Antibody-directed enzyme prodrug therapy: A review" <i>Drug Development Res.</i> (1995) 34(2):220-230	
	28	BALZARINI et al. "Highly Selective Cytostatic Activity of (E)-5-(2-Bromovinyl)-2'-deoxyuridine Derivatives for Murine Mammary Carcinoma (FM3A) Cells Transformed with the Herpes Simplex Virus Type 1 Thymidine Kinase Gene" <i>Molecular Pharmacology</i> (1985) 28:581-587	
	29	BALZARINI et al. "The cytostatic activity of 5-(1-azidovinyl)-2'-deoxyuridine (AzVDU) against herpes simplex virus thymidine kinase gene-transfected FM3A cells is due to inhibition of thymidylate synthase and enhanced by UV light ($\lambda = 254$ nm) exposure" <i>FEBS Lett.</i> (1995) 373:41-44	

Examiner Signature	L. E. Crane	Date Considered	04/01/2007
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SVCA_30870.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/782,721
		Filing Date	2/12/2001
		First Named Inventor	H. Michael Shepard
		Group Art Unit	1623
		Examiner Name	Crane, Lawrence E.
Date Submitted: April 13, 2006	Attorney Docket Number	NB 2004.02 (060925-0402)	
(use as many sheets as necessary)			
Sheet	3	of	9

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	30	BALZARINI et al. "Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives" <i>PNAS USA</i> (July 1996) 93:7295-7299	
	31	BARBATO et al. "Synthesis of bridged pyrimidine nucleosides and triazo [4, 3-c] pyrimidine nucleoside analogues" <i>Nucleosides & Nucleotides</i> (1989) 8(4):515-528	
	32	BARBATO, et al. "Synthesis of bridged pyrimidine nucleosides and triazo [4,3-c] pyrimidine nucleoside analogues" <i>Nucleos. Nucleot.</i> (1991) 10(4):853-866	
	33	BATHE et al. "Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival" <i>Cancer J. Sci. Am.</i> (1999) 5(1):34-40	
	34	BIBLE et al. "Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration" <i>Cancer Res.</i> (August 15, 1997) 57(16):3375-80	
	35	BLACKLEDGE "New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex')" <i>British J. Cancer</i> (1998) 77(Supp 2):29-37	
	36	CASS et al. "Recent advances in the molecular biology of nucleoside transporters of mammalian cells" <i>Biochem. Cell Biol.</i> (1998) 76(5):761-770	
	37	CATUCCI et al. "Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors" <i>J. Acquir. Immune Defic. Syndr.</i> (1999) 21:203-208	
	38	CHOU and TALALAY, "Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors" <i>Adv. Enzyme Regul.</i> (1984) 22:27-55	
	39	CORDON-CARDO and PRIVES "At the crossroads of inflammation and tumorigenesis" <i>J. Exp. Med.</i> (November 15, 1999) 190(10):1367-1370	
	40	COSTI et al. "Phthalen derivatives as a new tool for selectivity in thymidylate synthase inhibition" <i>J. Med. Chem.</i> (1999) 42(12):2112-2124	
	41	CRUICKSHANK et al. "Oligonucleotide labeling: A concise synthesis of a modified thymidine phosphoramidite" <i>Tetrahedron Lett.</i> (1988) 29(41):5221-5224	
	42	CURT "Cancer drug development: new targets for cancer treatment" <i>Oncologist</i> (1996) 1(3):II-III	

Examiner Signature	L. E. Crane 	Date Considered	04/01/2007
--------------------	---	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SVCA_30870.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/782,721
		Filing Date	2/12/2001
		First Named Inventor	H. Michael Shepard
		Group Art Unit	1623
		Examiner Name	Crane, Lawrence E.
Date Submitted: April 13, 2006		Attorney Docket Number	NB 2004.02 (060925-0402)
(use as many sheets as necessary)			
Sheet	4	of	9

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
He	43	CURTIN et al. "Mechanism of Cell Death following Thymidylate Synthase Inhibition: 2'-Deoxyuridine-5'-triphosphate Accumulation, DNA Damage, and Growth Inhibition following Exposure to CB3717 and Dipyridamole" <i>Cancer Res.</i> (May 1, 1991) 51:2346-2352	
	44	DeCLERCQ et al. "Antiviral Activity of Novel Deoxyuridine Derivatives" <i>Current Chemotherapy: Proceedings of the International Congress of Chemotherapy</i> (September 18, 1978) 1:352-354	
	45	DeCLERCQ "Antiviral Activity Spectrum and Target of Action of Different Classes of Nucleoside Analogues" <i>Nucleosides & Nucleosides</i> (1994) 13(6&7):1271-1295	
	46	DeCLERCQ "In search of a selective antiviral chemotherapy" <i>Clin. Micro. Review</i> (October 1997) 10(4):674-693	
	47	DOLNICK et al. "rTS Gene Expression is Associated with Altered Cell Sensitivity to Thymidylate Synthase Inhibitors" <i>Adv. Enzyme Reg.</i> (1996) 36:165-180	
	48	DRAKE et al. "Resistance to Tomudex (ZD1694): Multifactorial in Human Breast and Colon Carcinoma Cell Lines" <i>Biochem. Pharmacol.</i> (1996) 51(10):1349-1355	
	49	EDLER et al. "Immunohistochemically detected thymidylate synthase in colorectal cancer: An independent prognostic factor of survival" <i>Clinical Cancer Research</i> (February 2000) 6:488-492	
	50	FARROW et al. "Synthesis and biological properties of novel phosphotriesters: A new approach to the introduction of biologically active nucleotides into cells" <i>J. Med. Chem.</i> (1990) 33(5):1400-1406	
	51	FARRUGIA et al. "Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex®) in advanced colorectal cancer" <i>Eur. J. Cancer</i> (1998) 34(7):987-991	
	52	FREEMANTLE et al. "Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694" <i>British Journal of Cancer</i> (1995) 71:925-930	
He	53	GOEL et al. "Selective Intraperitoneal Biochemical Modulation of Methotrexate by Dipyridamole" <i>J. Clin. Oncol.</i> (February 1989) 7(2):262-269	
	54	GORLICK et al. "Drug Resistance in Colon Cancer" <i>Semin. Oncol.</i> (December 1999) 26(6):606-611	

Examiner Signature	L. E. Crane	Date Considered	04/01/2007
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SVCA_30870.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: April 13, 2006 (use as many sheets as necessary)		Application Number	09/782,721
		Filing Date	2/12/2001
		First Named Inventor	H. Michael Shepard
		Group Art Unit	1623
		Examiner Name	Crane, Lawrence E.
Sheet	5	of	9
		Attorney Docket Number	NB 2004.02 (060925-0402)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	55	GREM "Biochemical modulation of fluorouracil by dipyridamole: preclinical and clinical experience" <i>Semin Oncol.</i> (April 1992) 19(2 Suppl 3):56-65	
	56	GRIENGL et al. "Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'deoxyuridines: Synthesis and antiviral activity" <i>J. Med. Chem.</i> (1988) 31(9):1831-1839	
	57	GRIFFITH et al. "Differential Inhibition of Nucleoside Transport Systems in Mammalian Cells by a New Series of Compounds Related to Lidofazine and Miofazine" <i>Biochem. Pharmacol.</i> (1990) 40(10):2297-2303	
	58	HAN et al. "Dominant-negative p53 mutations in rheumatoid arthritis" <i>Arthritis Rheum</i> (1999) 42(6):1088-92	
	59	HEIDELBERGER et al. "Fluorinated pyrimidines and their nucleosides" <i>Adv. Enzymol. Related Areas Mol. Biol.</i> (1983) 54:57-119	
	60	HOLY et al. "Structure-Antiviral Activity Relationship in the Series of Pyrimidine and Purine N-[2-(2-Phosphonomethoxy)ethyl] Nucleotide Analogues. 1. Derivatives Substituted at the Carbon Atoms of the Base" <i>J. Med. Chem.</i> (1999) 42(12):2064-2086	
	61	HOWELL et al. "Comparison of the Synergistic Potentiation of Etoposide, Doxorubicin, and Vinblastine Cytotoxicity by Dipyridamole" <i>Cancer Res.</i> (June 15, 1989) 49:3178-3183	
	62	HU et al. "Determination of absorption characteristics of AG337, a novel thymidylate synthase inhibitor, using a perfused rat intestinal model" <i>J. Pharmaceutical Sciences</i> (July 1998) 87(7):886-890	
	63	HUSAIN et al. "Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy" <i>Cancer Research</i> (January 15, 1994) 54:539-546	
	64	JACKMAN "Folate-based thymidylate synthase inhibitors as anticancer drugs" <i>Ann. Oncol.</i> (1995) 6(9):871-881	
	65	JOHNSTON et al. "Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors" <i>Cancer Res.</i> (1995) 55:1407-1412	
	66	JONES and MANN "New methods of synthesis of β -aminoethylpyrazoles" <i>J. Am. Cancer Soc.</i> (1953) 75: 4048-4052	

Examiner Signature	L. E. Crane 	Date Considered	04/01/2007
--------------------	---	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SVCA_30870.1

09/782,721 - PRO-1449 #7

COPY FOR [] File ☒ Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: April 13, 2006 (use as many sheets as necessary)		Application Number	09/782,721
		Filing Date	2/12/2001
		First Named Inventor	H. Michael Shepard
		Group Art Unit	1623
		Examiner Name	Crane, Lawrence E.
Sheet	6	of	9
		Attorney Docket Number	NB 2004.02 (060925-0402)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
<i>[Signature]</i>	67	KOMAKI et al. "Difference in thymidylate synthetase activity in involved nodes compared with primary tumor in breast cancer patients" <i>Breast Cancer Res. Treat.</i> (1995) 35(2):157-162	
	68	KRAJEWSKA et al. "Pyrimidine ribonucleoside phosphorylase activity VS 5- and/or 6-substituted uracil and uridine analogues, including conformational aspects" <i>Biochem. Pharmacol.</i> (1982) 31(6):1097-1102	
	69	KRAUPP et al. "Membrane Transport of Nucleobases: Interaction with Inhibitors" <i>Gen. Pharmacol.</i> (1995) 26(6):1185-1190	
	70	LACKEY et al. "Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase" <i>Biochem. Pharmacol.</i> (2001) 61:179-189	
	71	LEE et al. "Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein" <i>Exp. Cell Res.</i> (1997) 234:270-276	
	72	LEHMAN et al. "Modulation of RTX cytotoxicity by thymidine and dipyridamole in vitro: implications for chemotherapy" <i>Cancer Chemother. Pharmacol.</i> (2000) 45:142-148	
	73	LEICHMAN et al. "Quantitation of Intratumoral Thymidylate Synthase Expression Predicts for Disseminated Colorectal Cancer Response and Resistance to Protracted-Infusion Fluorouracil and Weekly Leucovorin" <i>J. Clin. Oncol.</i> (October 1997) 15(10):3223-3229	
	74	LEICHMAN "Thymidylate synthase as a predictor of response" <i>Oncol.</i> (August 1998) 12(8):43-47	
	75	LENZ et al. "Thymidylate Synthase mRNA Level in Adenocarcinoma of the Stomach: A Predictor for Primary Tumor Response and Overall Survival" <i>J. Clin. Oncol.</i> (1995) 14(1):176-182	
	76	LENZ et al. "p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site" <i>Clinical Cancer Research</i> (May 1998) 4:1227-1234	
	77	LES et al. "Modeling of reaction steps relevant to deoxyuridylate (dUMP) enzymatic methylation and thymidylate synthase mechanism-based inhibition" <i>Journal of Biomolecular Structure & Dynamics</i> (1998) 15(4):703-715	
<i>[Signature]</i>	78	LEWIS et al. "Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies" <i>Cancer Immunol. Immunother.</i> (1993) 37(4):255-263	

Examiner Signature	L. E. Crane <i>[Signature]</i>	Date Considered	04/01/2007
--------------------	--------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SVCA_30870.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: April 13, 2006 (use as many sheets as necessary)		Application Number	09/782,721
		Filing Date	2/12/2001
		First Named Inventor	H. Michael Shepard
		Group Art Unit	1623
		Examiner Name	Crane, Lawrence E.
Sheet 7 of 9	Attorney Docket Number	NB 2004.02 (060925-0402)	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
<i>See</i>	79	LIVINGSTON et al. "Studies with tetrahydrohomofolate and thymidylate synthetase from amethopterin-resistant mouse leukemia cells" <i>Biochem.</i> (1968) 7(8):2814-2818	
	80	LOOK et al. "Increased thymidine kinase and thymidylate synthase activities in human epithelial ovarian carcinoma" <i>Anticancer Res.</i> (1997) 17:2353-2358	
	81	MADEC et al. "Some characteristics of fetal and adult isoenzymes of thymidine kinase in human breast cancers" <i>Bull. Cancer</i> (1998) 75:187-194	
	82	MADER et al. "Resistance to 5-fluorouracil" <i>Gen. Pharma.</i> (1998) 31(5):661-666	
	83	MAHALINGAM et al. "Structural and kinetic analysis of drug resistant mutants of HIV-1 protease" <i>Eur. J. Biochem.</i> (1999) 263:238-245	
	84	MAHONY et al. "Dipyridamole Kinetics" <i>Clin. Pharmacol. Ther.</i> (March 1982) 31(3):330-338	
	85	MALFAIT et al. "The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritis therapeutic in murine collagen-induced arthritis" <i>Proc. Natl. Acad. Sci.</i> (August 15, 2000) 97(17):9561-9566	
	86	MARINOVA-MUTAFCHIEVA et al. "A comparative study into the mechanisms of action of anti-tumor necrosis factor α , anti-CD4, and combined anti-tumor necrosis factor α /anti-CD4 treatment in early collagen-induced arthritis" <i>Arthritis and Rheumatism</i> (March 2000) 43(3):638-644	
	87	MASCIULLO et al. "The Rb family of cell cycle regulatory factors: clinical implications (review)" <i>Int. J. Oncol.</i> (2000) 17(5):897-902	
	88	MELTON et al. "Antibody-directed enzyme prodrug therapy (ADEPT). Review article" <i>Drugs of the Future</i> (1996) 21(2):167-181	
	89	MIDGLEY and KERR "Colorectal cancer" <i>Lancet</i> (Jan 30, 1999) 353:391-399	
	90	MULDER et al. "Thymidylate synthase levels in tumor biopsies from patients with colorectal cancer" <i>Anticancer Res.</i> (1994) 14(6B):2677-2680	
<i>See</i>	91	NELSON et al. "Potentiation of Methotrexate Toxicity by Dipyridamole" <i>Cancer Res.</i> (June 1984) 44:2493-2496	
	92	NICULESCU-DUVAZ et al. "Gene-directed enzyme prodrug therapy: A review of enzyme/prodrug combinations" <i>Expert Opin. Invest. Drugs</i> (1997) 6(6):685-703	

Examiner Signature	L. E. Crane <i>L. E. Crane</i>	Date Considered	04/01/2007
--------------------	--------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SVCA_30870.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/782,721
		Filing Date	2/12/2001
		First Named Inventor	H. Michael Shepard
		Group Art Unit	1623
		Examiner Name	Crane, Lawrence E.
Date Submitted: April 13, 2006		Attorney Docket Number	NB 2004.02 (060925-0402)
(use as many sheets as necessary)			
Sheet --	8	of	9

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	93	PARADISO et al. "Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients" <i>British J. of Cancer</i> (2000) 82(3):560-567	
	94	PATTERSON et al. "Thymidine phosphorylase moderates thymidine-dependent rescue after exposure to the thymidylate synthase inhibitor ZD1694 (tomudex) in vitro" <i>Cancer Res.</i> (1998) 58:2737-2740	
	95	PEDERSEN-LANE et al. "High-level expression of human thymidylate synthase" <i>Protein Expression and Purification</i> (1997) 10:256-262	
	96	PLUTA et al., "Synthesis and biological properties of 4-hydroxy, 4-thio-5-pyrimidine derivatives" <i>Boll. Chim. Farm.</i> (1999) 138(1):30-33	
	97	RAMU et al. "Circumvention of Adriamycin Resistance by Dipyridamole Analogues: A structure-activity relationship Study" <i>Int. J. Cancer</i> (1989) 43:487-491	
	98	ROMAIN et al. "Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer" <i>Int. J. Cancer</i> (1995) 61:7-12	
	99	ROONEY et al. "Comparative Genomic Hybridization Analysis of Chromosomal Alterations Induced by the Development of Resistance to Thymidylate Synthase Inhibitors" <i>Cancer Res.</i> (November 15, 1998) 58:5042-5045	
	100	ROTH et al. "p53 tumor suppressor gene therapy for cancer" <i>Oncology</i> (1999) 13(10)(5):148-154	
	101	SABOULARD et al. "Characterization of the activation pathway of phosphoramidate triester prodrugs of stavudine and zidovudine" <i>Mol. Pharmacol.</i> (1999) 56:693-704	
	102	SCHULTZ et al. "Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514" <i>Anticancer Res.</i> (1999) 19:437-444	
	103	TOUROUTOGLU et al. "Thymidylate synthase inhibitors" <i>Clin. Cancer Res.</i> (February 1996) 2(2):227-243	
	104	van LAAR et al. "Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer" <i>European J. Cancer</i> (1998) 34(3):296-306	
	105	van TRIEST et al. "Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer lines" <i>Clin. Cancer Res.</i> (1999) 5(3):643-654	

Examiner Signature	L. E. Crane 	Date Considered	04/01/2007
--------------------	---	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SVCA_30870.1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: April 13, 2006

(use as many sheets as necessary)

Complete if Known

Application Number	09/782,721
Filing Date	2/12/2001
First Named Inventor	H. Michael Shepard
Group Art Unit	1623
Examiner Name	Crane, Lawrence E.
Attorney Docket Number	NB 2004.02 (060925-0402)

Sheet 9 of 9

[illegible]

**Examiner
Signature**

L. E. Crane

Date Considered

04/01/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Uniquely citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

SVCA 30870.1

Substitution for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: May 8, 2006 Use as many sheets as necessary		Complete If Known	
		Application Number	09/782,721
Filing Date		February 12, 2001	
First Named Inventor		H. Michael SHEPARD	
Group Art Unit		1623	
Examiner Name		Crane, Lawrence E.	
Attorney Docket Number		060925-0402	
Sheet	1	of	1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
<i>ME</i>	1	5,998,151		Johnston et al.	12-07-1999	

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Application Document		Name of Patentee or Applicant of Cited Document	Filing Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
<i>ME</i>	2	BALZARINI et al. "Increased sensitivity of thymidine kinase-deficient (TK ⁻) tumor cell lines to the cell growth inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and related compounds" <i>Anticancer Research</i> (1986) 6:1077-1084	
	3	BALZARINI et al. "Marked inhibitory activity of masked aryloxy aminoacyl phosphoramidate derivatives of dideoxynucleoside analogues against visna virus infection" <i>J. Acquired Immune Deficiency Syndromes and Human Retrovirology</i> (1998) 17:296-302	
<i>ME</i>	4	HUGHEY et al. "Genetic variation in thymidylate synthase confers resistance to 5-fluorodeoxyuridine" <i>Novel Approaches to Selective Treatments of Human Solid Tumors: Laboratory and Clinical Correlation</i> (1993) Y.M. Rutum, ed., Plenum Press, N.Y., pp. 67-76	

Examiner Signature	L. E. Crane	Date Considered	04/01/2007
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SVCA_34070.1